Attovia Therapeutics Inc(ATTO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 37.71% | Shs Outstand | 45.6M | Perf Week | -1.89% |
| Market Cap | 0.66B | Forward P/E | - | EPS next Y | - | Insider Trans | 19.66% | Shs Float | 28.4M | Perf Month | -21.71% |
| Enterprise Value | 0.81B | PEG | - | EPS next Q | -0.56 | Inst Own | 15.65% | Short Float | 5.8% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 10.53% | Short Ratio | 3.64 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 1.65M | Perf YTD | -30.95% |
| Book/sh | -3.19 | P/C | 5.75 | EPS past 3/5Y | - | ROE | - | 52W High | -48.21% ($28.00) | Perf Year | - |
| Cash/sh | 2.52 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 12.06% ($12.94) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 10.84% 8.31% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.54 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.39 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 34.12 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.39 | Sales Q/Q | - | SMA20 | -9.24% ($15.98) | Beta | - | Target Price | $42.2 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/9/2 | SMA50 | -25.4% ($19.44) | Rel Volume | 0.42 | Prev Close | $14.18 |
| Employees | - | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -655.81% 42.09% | SMA200 | -25.56% ($19.48) | Avg Volume(3M) | 0.45M | Price | $14.5 |
| IPO | 2026/8/5 | Option/Short | No/Yes | Trades | 1774 | Volume | 189,149 | Change | 2.26% |
A clinical-stage biotech developing next-generation antibody therapeutics targeting immune-mediated diseases. Founded in 2023 and headquartered in the US, the company is building on its proprietary antibody engineering platform to develop candidates against already-validated therapeutic targets, using a subcutaneous route of administration.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded less than usual. That is 42% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 15.7%.
Tap to view numbers
It ranks #192 of 594 in the industry
Based on market cap of $662M.
SLDB#190 Solid Biosciences Inc $664M PER - 
LXRX#191 Lexicon Pharmaceuticals Inc $663M PER - ATTO#192 Attovia Therapeutics Inc $662M PER - 
WVE#193 Wave Life Sciences Inc $661M PER - 
DSGN#194 Design Therapeutics Inc $656M PER - 
FAQ
What kind of company is ATTO?
ATTO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATTO?
The market cap of ATTO is approximately $662M, ranking 2,916 within its sector.
What is the 52-week high and low for ATTO?
ATTO has recorded a 52-week high of $28.00 and a low of $12.94.
